Preoperative latanoprost to prevent ocular hypertension after phacoemulsification and intraocular lens implantation

J Cataract Refract Surg. 2001 Nov;27(11):1792-5. doi: 10.1016/s0886-3350(01)00902-6.


Purpose: To evaluate the efficacy of latanoprost given 2 hours preoperatively to prevent ocular hypertension in the early period after phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation.

Setting: Departments of Ophthalmology, United Christian Hospital and Prince of Wales Hospital, Hong Kong, China.

Methods: Sixty-four eyes of 64 patients with uncomplicated cataract having phacoemulsification with PC IOL implantation were included in this prospective randomized double-masked clinical trial. The eyes were randomly assigned to 1 of 2 groups: application of latanoprost 0.005% 2 hours before surgery or no latanoprost (control). Intraocular pressure (IOP) was measured 3 and 24 hours postoperatively. The anterior chamber was examined for the level of cells and flare using a slitlamp biomicroscope. The level of significance was 5%.

Results: The decrease in the mean IOP was not statistically significantly different between eyes receiving latanoprost 2 hours preoperatively and control eyes 3 hours (P =.843) and 24 hours (P =.721) postoperatively.

Conclusion: A single application of latanoprost given 2 hours before phacoemulsification and PC IOL implantation did not produce a statistically significant IOP-lowering effect when compared with a control group in the first 24 hours after surgery.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antihypertensive Agents / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Intraocular Pressure / drug effects*
  • Latanoprost
  • Lens Implantation, Intraocular / adverse effects*
  • Male
  • Ocular Hypertension / etiology
  • Ocular Hypertension / prevention & control*
  • Phacoemulsification / adverse effects*
  • Preoperative Care
  • Prospective Studies
  • Prostaglandins F, Synthetic / therapeutic use*
  • Treatment Outcome


  • Antihypertensive Agents
  • Prostaglandins F, Synthetic
  • Latanoprost